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This study compared the protective effects of three different anti-glycation compounds, aspirin, D-penicillamine and vitamin E, against high
glucose and advanced glycation endproduct (AGE) mediated toxicity in cultured bovine aortic endothelial cells using two approaches. Their
proliferation was assessed in culture in different concentrations of glucose (5.5–100 mmol/l) with and without these inhibitors. A monolayer of
cultured endothelial cells was wounded and recovery at the wound site was measured following exposure to different concentrations of glucose
with and without inhibitors. The ability of these compounds to protect cultured endothelial cells following exposure to bovine serum albumin-
derived advanced glycation endproducts (BSA-AGE) was also studied. Addition of glucose to cultured endothelial cells inhibited their
proliferation in a dose dependent manner. All three compounds protected against the anti-proliferative effects of high glucose, with vitamin E
being the most effective. The migration of cultured endothelial cells following wounding was inhibited by increasing concentrations of glucose but
was maintained in the presence of all three anti-glycation compounds with vitamin E, again giving the greatest protection. Vitamin E was also the
most effective at protecting against the anti-proliferative effects of BSA-AGE. D-penicillamine was not as effective as vitamin E whereas aspirin
offered no significant protection against AGE-induced cellular toxicity. Our studies suggest that compounds, such as vitamin E, with combined
antiglycation and antioxidant properties offer maximum therapeutic potential in protection against high glucose and AGE-mediated cellular
toxicity.
© 2006 Elsevier B.V. All rights reserved.Keywords: Glycation; Advanced glycation endproduct; Aspirin; D-penicillamine; Vitamin E; Wound healing; Endothelial cell; Diabetes; Antioxidant1. Introduction
The chronic hyperglycaemia of diabetes mellitus is believed
to have an important role in the pathogenesis of long-term
complications [1]. Hyperglycaemia may cause defective
angiogenesis with reduced endothelial cell proliferation,
migration and capillary tube formation, and this may underlie
diabetic complications such as impaired wound healing, stroke
and heart disease [2].Abbreviations: AGE, advanced glycation endproducts; FGF-2, fibroblast
growth factor-2; BSA, bovine serum albumin; 3-DG, 3-deoxyglucosone;
RAGE, receptors for advanced glycation endproducts; DMEM, Dulbecco's
Modified Eagle Medium; FCS, foetal calf serum; PBS, phosphate buffered
saline; ANOVA, one-way analysis of variance; NS, not significant
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doi:10.1016/j.bbadis.2006.02.004Hyperglycaemia-induced toxicity may occur by a number
of mechanisms [3] but perhaps the most attractive of these is
the role of protein glycation. Proteins are glycated by
nucleophilic addition of reducing sugars, such as glucose, to
free protein amino groups forming a labile Schiff base. This
rearranges to a more stable Amadori product that can
participate in slow but irreversible reactions, involving
intermediates such as 3-deoxyglucosones (3-DG), ultimately
giving rise to advanced glycation endproducts (AGEs). It is
believed that an increase in tissue and serum AGEs are
responsible for the vascular damage observed in diabetes [1].
This damage is compounded by production of free radicals
from the autoxidation of glucose and Amadori products [4]
and from interaction of AGEs with their cellular receptors
often abbreviated as RAGE [5,6].
The location and longevity of endothelial cells means they are
prime targets for hyperglycaemia-induced cell toxicity.
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esis of diabetic vascular complications [7]. Hyperglycaemia is
known to reduce the in vitro proliferation of endothelial cells
obtained from a number of sources, including the human
umbilical vein [8,9], bovine retina [10] and skin [11]. A
decreased cell density has been observed in the aortic
endothelium from diabetic rabbits possibly due to the anti-
proliferative effects of hyperglycaemia [12]. Hyperglycaemia
has also been shown to reduce migration of cultured endothelial
cells in vitro [13,14].
During hyperglycaemia, endothelial cells may be exposed to
circulating AGEs that have accumulated on small proteins or
peptides. Circulating serumAGEs increase in patients with renal
failure [15] and have been implicated in the high incidence of
vascular disease in such patients [16]. AGE-modified bovine
serum albumin (BSA-AGE) has been used to study AGE
toxicity on a number of cell types [17,18] and shown to be toxic
to mesangial cells [19], bovine aortic endothelial cells [20] and
retinal pericytes [21]. This toxicity is mediated via production of
free radicals, particularly when AGEs interact with their
receptors on the cell surface [5,6].
There is considerable interest in compounds that can protect
against glucose-induced cellular damage because of their
therapeutic potential. Such compounds may act by (i) protecting
protein amino groups available for glycation; (ii) blocking
carbonyl groups on Amadori products and 3-DG thus reducing
AGE formation or (iii) protecting against glucose and AGE-
derived free radicals.
In this study, we investigated and compared three
compounds, aspirin (acetylsalicylic acid), D-penicillamine and
vitamin E (α-tocopherol) that act by different mechanisms, to
determine their protective effects against the antiproliferative
effects of high glucose and AGEs and the effects of high
glucose on cellular migration.
2. Materials and methods
2.1. Materials
Dulbecco's Modified Eagle Medium (DMEM) was obtained from Gibco
(Paisley, Scotland) and foetal calf serum (FCS) from ICN Biochemicals Ltd.
(Basingstoke, UK). Aspirin, D-penicillamine, vitamin E and all other reagents
were obtained from Sigma (Poole, UK).
2.2. Preparation of BSA-AGE
Bovine serum albumin (10 mg/ml) was incubated in 250 mmol/l glucose in
100 mmol/l sodium phosphate buffer containing 3 mmol/l sodium azide, pH 7.4
at 37 °C for 5 weeks. The glycated albumin was dialysed exhaustively against
distilled water at 4 °C, lyophilised and stored at −20 °C. The formation of AGEs
was assessed by their characteristic fluorescence emission spectra at 410 nm
after excitation at 350 nm using a Luminescence Spectrometer (Model LS30).
Before addition to cell cultures, BSA-AGE was dissolved in distilled water and
filtered through a sterile 0.2 μm filter.
2.3. Culture of bovine aortic endothelial cells
Bovine aortic endothelial cells were characterised as described previously
[22] and cultured in DMEM supplemented with 15% FCS, 2 mmol/l glutamine,
1 U/l penicillin and 100 μg/ml streptomycin. They were cultured in a filtercap flask at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. All
cultures were used between passages 5–10 and within 3 weeks of
establishing the culture. Cell viability was 100% as determined by trypan
blue exclusion.
2.4. Effect of high glucose on cell proliferation
Cells were trypsinised with 1% w/v trypsin, centrifuged at 1000×g for
5 min and resuspended in DMEM containing 15% FCS. A 1 ml syringe and
0.5×25 mm sterile needle was used to prepare a single cell suspension.
Approximately 2×104 cells/ml (2 ml/well) were placed into six well plates
and seeded at 37 °C for 6 h. The medium was removed and cells were
rinsed briefly with phosphate buffered saline (PBS), pH 7.4. Fresh DMEM
containing 5.5–100 mmol/l glucose was added (2 ml/well). Aspirin, D-
penicillamine and vitamin E were dissolved in 10 mmol/l sodium phosphate
buffer, pH 7.4 and filtered through a 0.2 μm sterile filter before addition to
cell cultures. Aspirin, D-penicillamine and vitamin E were added to final
concentrations of 0–1000 μmol/l to the endothelial cells grown in
100 mmol/l glucose. The final FCS concentration was 15%. Proliferation of
cultured cells was assessed by determining the mean of three experiments
each with six wells as described below.
2.5. Effect of BSA-AGE on cell proliferation
Before addition to cell cultures, BSA-AGE was dissolved in distilled water
and filtered through a 0.2-μm filter. DMEM containing 2×104 cells / ml (2 ml/
well) was transferred to six well plates and cells were seeded for 6 h. The
medium was replaced with fresh DMEM containing 5.5 mmol/l glucose. BSA-
AGE was added to the culture medium to a final concentration of 50 μg/ml. Our
previous studies using different concentrations of BSA-AGE have shown that
this concentration was most effective at reducing cellular proliferation [20].
Aspirin and D-penicillamine were added to a final concentration of 200 and
vitamin E to 100 μmol/l to endothelial cells cultured in the presence of 50 μg/ml
of BSA-AGE. The final FCS concentration was 2.5%. Proliferation of cells was
assessed as below.
2.6. Counting of bovine aortic endothelial cells
After 72–120 h, the medium was removed and the wells were rinsed with
2 ml PBS, pH 7.4. Cells were trypsinised with 1% w/v trypsin (500 μl/well) for
5 min. DMEM (500 μl/well) was added to neutralise the trypsin. Single cell
suspensions were prepared using a 1 ml syringe and sterile needle. The cell
suspensions (1 ml) were mixed with 15 ml of isoton and counted using an
Industrial D coulter counter (model F2 3AG).
2.7. Effect of high glucose on cell migration
Single cell suspensions were prepared and 2×105 cells were added to each
well of a 24-well plate containing cover slips in normal medium. The cells were
cultured at 37 °C in a humidified atmosphere of 5% CO2 and 95% air until
confluent. They were then rinsed with PBS and cultured in 5.5–100 mmol/
l glucose with or without 200–500 μmol/l aspirin, D-penicillamine or vitamin E,
respectively, for 20 h. After this period, the cover slips were removed, rinsed
with PBS and the cellular layer wounded using a razor blade and rinsed again
with PBS to remove loose or dislodged cells [23]. These cover slips were either
fixed immediately (controls) or replaced in fresh 24-well plates containing 1 ml
medium with either 5.5–100 mmol/l glucose with and without inhibitors and
incubated for 20 h. The medium was discarded and cells rinsed with PBS before
fixation in 70% ethanol for 5 min. The ethanol was then removed and the cover
slips were left at room temperature until dry. The cells were stained with
bromophenol blue for 1 min before being washed and left to dry at room
temperature. Movement of cells into the denuded area was quantified using a
Seescan computerized image analysis system. For each coverslip, 5 fields of
view (each ~1.5 mm long) were examined at random. The lesion area in each
field of view was measured and using the data from time 0 (T0), the wound area
was then converted to give mean percent recovery from 3 identically treated
coverslips.
Fig. 1. Proliferation of endothelial cells cultured in 5.5–100 mmol/l glucose for
120 h. Proliferation is expressed as a percentage of that for endothelial cells
cultured in 5.5 mmol/l glucose alone. Results are presented as mean±S.D.
(n=3). *P<0.05 vs. 5.5 mmol/l glucose.
Fig. 3. Proliferation of endothelial cells cultured in 5.5 or 100 mmol/l glucose
±0–1000 μmol/l D-penicillamine for 120 h. Proliferation is expressed as a
percentage of that for endothelial cells cultured in 5.5 mmol/l glucose alone.
Results are presented as mean±S.D. (n=3). *P<0.05 vs. 100 mmol/l glucose.
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Results are expressed as mean±S.D. (n=3) and the statistical significance
between groups and controls was determined using one-way analysis of variance
(ANOVA) on cell numbers.3. Results
3.1. Effect of high glucose on cell proliferation
Vitamin E and to a lesser extent D-penicillamine and
aspirin protect against glucose-induced inhibition of cell
proliferation. Proliferation of endothelial cells exposed to 25,
50 and 100 mmol/l glucose was reduced to 92±6%, 81±2%
and 57±7%, respectively, of that in physiological (5.5 mmol/l)
glucose (Fig. 1).
The presence of 50, 200, 500 and 1000 μmol/l of aspirin
increased the proliferation of endothelial cells grown in
100 mmol/l glucose to 53±4%, 54±5%, 84±2% and 79±4%,
respectively, of that in cells grown in 5.5 mmol/l glucose alone
(Fig. 2).
D-penicillamine also protected against the anti-proliferative
effect of 100 mmol/l glucose although it was less effective thanFig. 2. Proliferation of endothelial cells cultured in 5.5 or 100 mmol/l glucose
±0–1000 μmol/l aspirin for 120 h. Proliferation is expressed as a percentage of
that for endothelial cells cultured in 5.5 mmol/l glucose alone. Results are
presented as mean±S.D. (n=3). *P<0.05 vs. 100 mmol/l glucose.aspirin at higher concentrations. In the presence of 50, 200,
500 and 1000 μmol/l of D-penicillamine, proliferation of
endothelial cells grown in 100 mmol/l glucose was 55±1%,
63±4%, 79±3% and 50±13%, respectively, of that in cells
grown in 5.5 mmol/l glucose alone (Fig. 3).
Vitamin E was particularly effective in protecting against
the anti-proliferative effects of high glucose, particularly at
concentrations above 200 μmol/l. In the presence of 50, 200,
500, 1000 μmol/l of vitamin E, proliferation of endothelial
cells grown in 100 mmol/l glucose was 38±16%, 63±9%,
110±4% and 112±10%, respectively, of that in cells grown
in 5.5 mmol/l glucose alone (Fig. 4).
3.2. Effect of BSA-AGE on cell proliferation
Vitamin E, D-penicillamine and aspirin protect against the
inhibitory effect of BSA-AGE on cell proliferation. The
proliferation of endothelial cells cultured in 50 μg/ml of BSA-
AGE was reduced to 54±4% of the control containing no BSA-
AGE (P<0.01, Fig. 5). Cells were, however, protected against
the toxic effects of BSA-AGE by 100 μmol/l of vitamin E where
proliferation was improved to 74±4% (P<0.05) and to a lesserFig. 4. Proliferation of endothelial cells cultured in 5.5 or 100 mmol/l glucose
±0–1000 μmol/l vitamin E for 120 h. Proliferation is expressed as a percentage
of that for endothelial cells cultured in 5.5 mmol/l glucose alone. Results are
presented as mean±S.D. (n=3). *P<0.05 vs. 100 mmol/l glucose.
Fig. 5. Proliferation of endothelial cells cultured in 5.5 mmol/l glucose±50 μg/
ml BSA-AGE±200 μmol/l aspirin or D-penicillamine or 100 μmol/l vitamin E
for 72 h. Proliferation is expressed as a percentage of that for endothelial cells
cultured in 5.5 mmol/l glucose alone. Results are presented as mean±S.D.
(n=3). *P<0.01 vs. 0 μg/ml of BSA-AGE, **P<0.05 vs. 50 μg/ml of BSA-
AGE.
Fig. 6. (a) Migration of endothelial cells cultured in (i) 5.5, (ii) 30 and (iii) 100 mmol/
effects of (iv) 200 (v) 500 μmol/l aspirin, (vi) 200 (vii) 500 μmol/l D-penicillamine an
by these endothelial cells cultured in (i) 5.5, (ii) 30 and (iii) 100 mmol/l glucose for 1
200 (v) 500 μmol/l aspirin, (vi) 200 (vii) 500 μmol/l D-penicillamine and (viii) 200 (ix
*P<0.05 vs. 5.5 mmol/l glucose.
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61±3% (P<0.1).
Proliferation of cells exposed to 50 μg/ml of BSA-AGE in
the presence of aspirin was 57±9% of the control and did not
differ significantly from that in 30 mmol/l glucose alone.
3.3. Effect of high glucose on cell migration
The migration of cells in 5.5 mmol/l glucose was 0.54±
0.11 mm (Fig. 6a (i) and 6b). Migration of cells wounded in
30 mmol/l glucose was decreased (P<0.05) with distance
reduced to 0.36±0.06 mm (Fig. 6a (ii) and 6b). A decreased
migration was seen in cells wounded in 100 mmol/l glucose
(P<0.05) where movement was only 0.15±0.03 mm (Fig. 6a
(iii) and 6b). The migration of cells wounded in 100 mmol/
l glucose with 200 μmol/l aspirin was 0.20±0.04 mm (Fig. 6a
(iv) and 6b) compared with a value of 0.43±0.07 mm for those
wounded in 100 mmol/l glucose and 500 μmol/l aspirin (Fig. 6a
(v) and 6b). Migration of cells cultured in 100 mmol/l glucose
containing 200 and 500 μmol/l of D-penicillamine were 0.25±l glucose for 120 h. These cells were also cultured in 100 mmol/l glucose and the
d (viii) 200 (ix) 500 μmol/l vitamin E is shown. (b) Shows the distances migrated
20 h. These cells were also cultured in 100 mmol/l glucose and the effects of (iv)
) 500 μmol/l vitamin E is shown. The results are presented as mean±S.D. (n=3).
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However, vitamin E was effective in restoring migration of
endothelial cells cultured in 100 mmol/l glucose. Its inclusion at
200 and 500 μmol/l resulted in migration distances of 0.47±
0.10 and 0.60±0.10 mm (Figs. 6a (viii, ix) and 6b),
respectively.
4. Discussion
In this study, we have compared the abilities of three
compounds to protect endothelial cells against high glucose and
AGE-induced cellular toxicity. We have used well characterised
primary vascular endothelial cells to demonstrate glucose-
induced inhibition of cell proliferation in vitro. An increasing
concentration of glucose inhibits proliferation of endothelial
cells in vitro. Our results confirm those of other workers who
found that high glucose inhibits proliferation of endothelial cells
in vitro [9,8,11]. Circulating concentrations of glucose can
range from around 10 mmol/l to >50 mmol/l in severely
untreated diabetic patients. In our in vitro model system of
vascular endothelial cells, we chose concentrations from 25–
100 mmol/l to represent a range corresponding to moderate to
severe diabetic conditions. Although these concentrations are
toward the upper limit of those seen in physiological conditions,
taking into account that normal ideal growth conditions for
these cells in vitro include medium supplementation with
25 mmol/l glucose, in this experimental system, to induce
glucose specific effects over the short exposure times required
additional increases determined from our pilot data. The
normal growth medium was supplemented with an additional
25 mmol/l for the majority of experiments as this concentra-
tion induced a reduction in angiogenic activity of these cells.
This concentration is similar to that used in other similar
studies investigating the effects of glucose on protein glycation
and oxidative stress in macrovessel and microvessel endothe-
lial cells [24,25]. Glucose-induced toxicity cannot be
accounted for by hyperosmolality as previous studies by our
group have shown that mannitol supplemented to an
equivalent concentration of glucose failed to suppress
proliferation of bovine aortic endothelial cells [20]. During
hyperglycaemia, the concentration of intracellular sugars, such
as glucose-6-phosphate, fructose-6-phosphate and glyceralde-
hyde-3-phosphate, increase and all are more reactive than
glucose [26,27]. Build-up of these reactive intracellular sugars
may increase glycation of stored fibroblast growth factor-2
(FGF-2). Indeed, glycated FGF-2 has reduced mitogenic
activity and when added to cultured endothelial cells decreases
their proliferation compared to native FGF-2 [28,29,20].
Hyperglycaemia increases formation of AGEs and addition
of BSA-AGE to the culture medium also reduces proliferation
of endothelial cells. This confirms findings by other workers
who showed reduced proliferation of mesangial cells [19] and
retinal pericytes [30] when exposed to AGEs in culture. In
addition to endogenous AGEs, some may have an exogenous
origin, i.e., derived from food [31] or smoking [32]. Recent
studies have shown that increased consumption of exogenous
dietary AGEs can delay wound healing in diabetic mice [33].This glucose and AGE-induced anti-proliferative effect is
believed to contribute towards the chronic vascular complica-
tions of diabetes. Furthermore, our studies have shown that high
glucose inhibits the migratory abilities of endothelial cells.
Previous work has suggested that high glucose induces
activation of nuclear factor kappa B (NF-κB) which inhibits
endothelial cell migration [14].
In this study, vitamin E was most effective in protecting cells
against glucose- and AGE mediated toxicity. Vitamin E is a
naturally occurring lipid soluble antioxidant capable of crossing
cell membranes and has been shown to protect against glycation
and AGE formation [34,35]. Vitamin E has been shown to
reduce glycated haemoglobin in type 1 diabetic patients [36]
and also protect against diabetic nephropathy in diabetic rats
[37]. Although the precise mechanism for protection is unclear,
it has been suggested that vitamin E is a potent reducing agent
and competes with glucose for protein amino groups [34].
Vitamin E also prevented the glucose-mediated formation of
intracellular AGEs in cultured bovine aortic endothelial cells
[38], and reduced membrane lipid peroxidation and expression
of peroxidation products including malondialdehyde of RBCs
treated with high glucose [39,40]. Vitamin E could also protect
intracellular FGF-2 against glycation and free radical damage
thus improving proliferation of endothelial cells.
D-penicillamine is an anti-rheumatic drug and has been
shown to reduce AGE-derived protein cross-linking [41]
probably by blocking carbonyl groups on Amadori products,
3-DG or free sugars. D-penicillamine was less effective than
vitamin E in improving proliferation and migration of cultured
cells in high glucose. Furthermore, D-penicillamine was less
effective at protection against the anti-proliferative effects of
BSA-AGE, possibly because vitamin E is a more potent
antioxidant. Previous work has suggested that D-penicillamine
could act as a ‘glyoxal trap’ protecting cells against the
cytotoxic effects of lipid peroxidation products produced in
diabetic patients [42], or may act as a transglycating agent,
inhibiting glycation [43].
Aspirin has been shown to inhibit glycation of lens crystallin
and collagen [44,45]. Aspirin improved proliferation and
migration of endothelial cells cultured in high glucose but
failed to protect against AGE-mediated toxicity. This suggests
that blocking of glycation by acetylation of amino groups is
significant in reducing glucose- but not AGE-mediated cellular
toxicity. Metabolites of aspirin (2,5- and 2,3-dehydroxybenzoic
acid; DHBA) have previously been shown to inhibit LDL
oxidation in human umbilical vein endothelial cells, suggesting
a potential protective mechanism via free radical scavenging
[46]. Our data contrast with those of other workers who could
not demonstrate any protective effect of aspirin against high
glucose in cultured endothelial cells [47].
Since previous studies have shown that glucose and AGEs
mediate their toxicity in part, by the generation of free
radicals and glycoxidation reactions, it is logical to hypothe-
sise that the compounds tested here are protective against
these processes. We have shown that glucose supplementation
(50 mmol/l) is sufficient to induce increased cellular apoptosis
as well as expression of reactive oxygen species and lipid
556 J. Zhang et al. / Biochimica et Biophysica Acta 1762 (2006) 551–557peroxidation in cultured bovine aortic endothelial cells (data
not included). As part of our ongoing research programme,
we are currently investigating the mechanisms through which
vitamin E, D-penicillamine and aspirin exert their protective
actions. Increasing evidence suggests that glucose and AGE-
mediated cellular toxicities are responsible for the vascular
complications of diabetes mellitus. Natural compounds, such
as vitamin E, which have combined anti-glycation and
antioxidant properties are likely to offer maximum therapeutic
potential.
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